Managing reversal of direct oral anticoagulants in emergency situations: Anticoagulation education task force white paper

Thrombosis and Haemostasis

Volumn 116, Issue 5, 2016, Pages 1003-1010

  Ageno, Walter ^a   Büller, Harry R ^b   Falanga, Anna ^c   Hacke, Werner ^d   Hendriks, Jeroen ^e,f   Lobban, Trudie ^g   Merino, Jose ^h   Milojevic, Ivan S ⁱ   Moya, Francisco ^j   van der Worp, H Bart ^k   Randall, Gary ^l   Tsioufis, Konstantinos ^m   Verhamme, Peter ⁿ   Camm, A John ^o,p  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f LINKÖPING UNIVERSITY   (Sweden)

^g Arrhythmia Alliance and AF Association   (United Kingdom)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ General Hospital of uprija   (Serbia)

^j Vithas Xanit International Hospital   (Spain)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^l Stroke Alliance For Europe (SAFE)   (United Kingdom)

^m UNIVERSITY OF ATHENS   (Greece)

ⁿ UNIVERSITY OF LEUVEN   (Belgium)

^o ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^p IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Anticoagulation; Atrial fibrillation; Reversal agents; Stroke prevention; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; VITAMIN K GROUP; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; IDARUCIZUMAB; MONOCLONAL ANTIBODY;

ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EDUCATION; EMERGENCY; HUMAN; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIDE EFFECT; VENOUS THROMBOEMBOLISM; ADVISORY COMMITTEE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADVISORY COMMITTEES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; DABIGATRAN; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; RIVAROXABAN;

EID: 84992339321     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-05-0363     Document Type: Article

References (36)

1. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012; 142: 1489–1498.
2. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013; 167: 1807–1824.
3. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837–847.
4. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–1457.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
6. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.
7. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.
8. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
9. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.
10. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in „real-world“patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264–2273.
11. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157–164.
12. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2015; Epub ahead of print.
13. Ageno W, Mantovani LG, Haas S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016; 3: e12–21.
14. Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest P. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e24S-43S.
15. Warfarin [SmPC]. Taro Pharmaceuticals UK Limited 2013.
16. Fasco MJ, Principe LM. R-and S-Warfarin inhibition of vitamin K and vitamin K 2, 3-epoxide reductase activities in the rat. J Biol Chem 1982; 257: 4894–4901.
17. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e44S-88S.
18. Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 2015; 39: 395–402.
19. Lange J, Thiel C, Thiel K, et al. Acceration of dabigatran elimination by activated charcoal perfusion and hemodialysis in a pig model. ASH Annual Meeting Abstracts 2012; 120 2272.
20. Praxbind (Idarucizumab) injection for intravenous use [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT. October 2015.
21. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386: 680–690.
22. Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511–520.
23. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943–951.
24. Glund S, Stangier J, Schmol M, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood 2014; 124: 344.
25. Pollack CV, Jr., Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114: 198–205.
26. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015.
27. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446–451.
28. Crowther M, Levy G, Lu G, et al. A phase 2 randomized, double-blind, placebocontrolled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Presented at the 56th annual meeting of the American Society of Hematology, San Francisco, December 6–9, 2014.
29. Crowther M, Lu G, Conley PB. Reversal of factor Xa inhibitors-induced anticoagulation in healthy subjects by andexanet alfa. Crit Care Med 2014; 42: A1469.
30. Crowther M, Mathur V, Kitt M, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. Presented at the 55th annual meeting of the American Society of Hematology, New Orleans, December 7–10.
31. Crowther M, Kittl E, Lorenz T, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors 20. 1. J Thromb Haemost 2013; 11 (Suppl 2): Abstract.
32. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113: 931–942.
33. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371: 2141–2142.
34. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325–2332.
35. Levy JH, Ageno W, Chan WC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH. J Thromb Haemost 2015; in press.
36. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34: 2094–2106.